For example, a treatment regimen aimed at targeting the tumor stem cell marker ITGA4 may result in undesired effects owing to the high expression of ITGA4 in immune cells other than tumor cells, as illustrated in Fig. 1A (Ruan et al. 2020). Here, ITGA4 is linked to neoplasm.